Hexal welcomes Lamminger as its newest board member
Susanne Lamminger, a seasoned professional in the pharmaceutical industry, has recently taken on new roles in prominent German companies. As of February 2024, she serves as the Head of Corporate Affairs at Sandoz Germany, a position she has held for over a year. In July 2025, she was appointed as a Board Member at Hexal AG, further expanding her influence in the German pharmaceutical sector.
Lamminger's career trajectory began in the political sphere, with experience working in both the Bundestag (German Federal Parliament) and the European Parliament. Although the specific roles and dates are not detailed, her background in politics has undoubtedly contributed to her expertise in health policy and public affairs.
From 2018 to 2024, Lamminger served as the Director of Health Policy at Bayer, where she shaped the company’s engagement with healthcare stakeholders. Prior to this, she held the position of Referentin Länderkoordinierung at the Verband Forschender Arzneimittelhersteller (VFA), a German pharmaceutical industry association, between 2012 and 2017. Her responsibilities included coordinating regional affairs and focusing on liaison and policy coordination.
In July 2025, Lamminger was elected as the chairwoman of the regional Bavarian chapter of Pharma Deutschland, Pharma Deutschland Landesverband Bayern. This appointment further underscores her leadership in policy and industry representation.
Here is a summary of her career progression:
| Period | Role | Organization | |------------------|--------------------------------------|----------------------------------------| | 2025–present | Board Member | Hexal AG | | 2024–present | Head of Corporate Affairs | Sandoz Germany | | 2025–present | Chairwoman | Pharma Deutschland Landesverband Bayern| | 2018–2024 | Director Health Policy | Bayer | | 2012–2017 | Referentin Länderkoordinierung | VFA | | Early career | Roles in Bundestag & European Parliament | Not specified (background noted) |
Lamminger's career reflects a steady progression from policy coordination and parliamentary work to senior leadership in corporate public affairs and industry representation, with a consistent focus on health policy and pharmaceutical regulation.
In her new roles at Sandoz Germany and Hexal AG, Susanne Lamminger utilizes her expertise in public affairs to shape the financial and business strategies of these prominent German companies within the pharmaceutical industry. As the Chairwoman of the regional Bavarian chapter of Pharma Deutschland, she continues to advocate for policy changes that impact the sector's finance and business operations.
